Pfizer Inc (NYSE:PFE) shares declined 1.15% to $26.74 in premarket trading Monday, even after the pharmaceutical company ...

Income investors tend to gravitate towards covered calls, and blue-chip high yielding stocks are a great place to start.

This healthcare giant is trading at a discounted price today.

These companies' shares have fallen too far, offering investors an attractive opportunity.

Pfizer shares have emerged as a compelling contrarian investment opportunity as the pharmaceutical giant trades at historically attractive valuations following an extended period of market skepticism.

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. The big US drugmaker pointed to another drop in ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

Pfizer (NYSE: PFE) recently reported earnings, and its payout ratio is once again over 100%. Given that the stock is paying a fairly high yield of 6.4%, which is far above the S&P 500 average of 1.2%, ...

Pfizer delivered strong 3Q25 results, beating EPS and revenue estimates, and raised full-year EPS guidance while maintaining robust cost-saving targets. PFE's $10B acquisition of Metsera secures a ...